Monday, August 30, 2021 5:00:00 AM
123tom:
I started (after military service) as a young guy in commodities (25) and working with one of the biggest commodity traders in Germany with Merrill Lynch Intl (7 years) and learning point and figure charting and tape reading, bar charts (by hand) for him as he barked orders to the various floors and used the Richard D Wyckoff Method,
I returned from Europe in 1971 and worked for PaineWebber (6 years & now part of UBS) working there because my salary in Germany was in US dollars and the dollar was down 50% from the exchange from D-Marks to dollars & I then had a family with 2 girls born in Frankfurt, one in 1969 and the other in 1971.
The rest of my career was with Morgan Stanley and lasted 26 years before I retired in 2004 as SVP at age 60. I was burnt out & my wife said..."Why did you quit? You watch the markets all day long"....lol
Elliott Wave is good, especially for indexes, not always good for stocks and Fibonacci is part of their system. The constant count revisions is the reason many step away. The best analyst for Elliott Wave was Tony Caldaro who died in recent years...he was really good and had his own "Objective Elliott Wave"...naturally I followed Robert Prechter, but Tony was, imo, more accurate.
Yes, I did follow Joe Granville, especially like his On Balance Volume (OBV) for stocks holding up well on declines; it works well.
I use other methods, too. Super Star Robert Farrell (Merrill Lynch), Rick Bensignor (Morgan Stanley...he worked in the C-Suite) Tom DeMark (worked with many hedge fund people...like Michael Steinberg who actually donated a residence building where I took executive training at Wharton....many others along the way have given me a good trading education in TA, but I now like to keep it very simple and use only various technical indicators, patterns, formations, etc along with Volume readings. I like MACD, OBV, RSI and look for divergent signals such as a new high in stock price not confirmed by the RSI.
Wish I understood the science of $AVXL much better, so I do rely on the science people here; it helps a LOT....best
I started (after military service) as a young guy in commodities (25) and working with one of the biggest commodity traders in Germany with Merrill Lynch Intl (7 years) and learning point and figure charting and tape reading, bar charts (by hand) for him as he barked orders to the various floors and used the Richard D Wyckoff Method,
I returned from Europe in 1971 and worked for PaineWebber (6 years & now part of UBS) working there because my salary in Germany was in US dollars and the dollar was down 50% from the exchange from D-Marks to dollars & I then had a family with 2 girls born in Frankfurt, one in 1969 and the other in 1971.
The rest of my career was with Morgan Stanley and lasted 26 years before I retired in 2004 as SVP at age 60. I was burnt out & my wife said..."Why did you quit? You watch the markets all day long"....lol
Elliott Wave is good, especially for indexes, not always good for stocks and Fibonacci is part of their system. The constant count revisions is the reason many step away. The best analyst for Elliott Wave was Tony Caldaro who died in recent years...he was really good and had his own "Objective Elliott Wave"...naturally I followed Robert Prechter, but Tony was, imo, more accurate.
Yes, I did follow Joe Granville, especially like his On Balance Volume (OBV) for stocks holding up well on declines; it works well.
I use other methods, too. Super Star Robert Farrell (Merrill Lynch), Rick Bensignor (Morgan Stanley...he worked in the C-Suite) Tom DeMark (worked with many hedge fund people...like Michael Steinberg who actually donated a residence building where I took executive training at Wharton....many others along the way have given me a good trading education in TA, but I now like to keep it very simple and use only various technical indicators, patterns, formations, etc along with Volume readings. I like MACD, OBV, RSI and look for divergent signals such as a new high in stock price not confirmed by the RSI.
Wish I understood the science of $AVXL much better, so I do rely on the science people here; it helps a LOT....best
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
